NCT03616496View on ClinicalTrials.gov

Assessment of 18F-Florbetaben Whole-body PET for the Detection of Cardiac and Extracardiac Sites of Amyloid Deposits

NACompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

June 6, 2019

Primary Completion Date

January 30, 2025

Study Completion Date

February 10, 2025

Conditions
Cardiac Amyloidosis
Interventions
DRUG

Neuraceq PET/CT imaging

PET/CT with Neuraceq injection, blood and urine sampling for protein electrophoresis, bone scintigraphy for the three arm (if the exams are present in the patient's medical record and are less than 3 months old, they do not need to be repeated

Trial Locations (1)

54511

Chru Nancy, Vandœuvre-lès-Nancy

All Listed Sponsors
lead

Central Hospital, Nancy, France

OTHER

NCT03616496 - Assessment of 18F-Florbetaben Whole-body PET for the Detection of Cardiac and Extracardiac Sites of Amyloid Deposits | Biotech Hunter | Biotech Hunter